Study: Tralokinumab Shows More Frequent Injection Site Reactions Than Dupilumab in Patients With AD

Although injection site reactions were common occurrences in both the tralokinumab and dupilumab groups, tralokinumab caused ISRs more frequently.

Related Keywords

Italy , ,Image Credit ,Dermatology Unit ,Naples Federico ,Numerical Rating Scale ,Atopic Dermatitis ,Dupilumab ,Tralokinumab ,Injection Site Reactions ,